Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant
Status:
Withdrawn
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well carfilzomib and dexamethasone work in treating patients
with multiple myeloma who previously underwent a stem cell transplant. Carfilzomib may stop
the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Immunosuppressive therapy, such as dexamethasone, may improve bone marrow function and
increase blood cell counts. Giving carfilzomib together with dexamethasone may be an
effective treatment for multiple myeloma.